ABVX

The most significant catalyst was a report from French publication La Lettre, which claimed that representatives from Eli Lilly had met with France’s Treasury in early December to assess the regulatory framework surrounding a potential acquisition of Abivax. This report reignited speculation about a possible takeover, leading to a sharp increase in the stock price. Although Reuters could not immediately confirm the report, the market reacted strongly to the news. Eli Lilly has been consistently silent on such speculation, reiterating that it does not comment on “business development activity”. Abivax has also remained tight-lipped, not commenting on market rumors or speculation. The market, however, is buzzing with the possibility of a strategic alliance or acquisition between the two companies.

Another factor contributing to the stock's rise was Abivax's announcement of its inclusion in the Nasdaq Biotechnology Index (NBI), effective before the market opened on December 22, 2025. This move can attract attention from investors, as it may trigger mechanical buying by funds that track the index. Although the impact is often short-lived, it can still influence stock prices, especially for companies that are newly added to the index.